Home/Pipeline/Ultra-Compact Type V Nuclease

Ultra-Compact Type V Nuclease

In vivo genome editing (all-in-one AAV delivery)

ResearchActive

Key Facts

Indication
In vivo genome editing (all-in-one AAV delivery)
Phase
Research
Status
Active
Company

About Metagenomi

Metagenomi is pioneering a new era of genetic medicine by harnessing the vast diversity of microbial life through metagenomics to discover and engineer next-generation genome editing tools. Founded by pioneers in the field, the company has built an industry-leading database, identified over 20,000 editing systems, and is advancing a pipeline of in vivo therapies for genetic diseases. With a strong leadership team, strategic partnerships, and a public listing, Metagenomi is positioned to expand its therapeutic reach and translate its novel platform into transformative patient cures.

View full company profile